News
Pediatric and adult patients experienced noninferior and robust immune responses to RIV4, as well as similar safety profiles.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback